ESR1 and breast cancer: The difference between the two databases may be due to race because a retrospective study from South Korea showed that ER−/PR+ patients accounted for 9.4% of all patients with BC [24] and another study from China reported that the proportion of ER−/PR+ patients was 11% [25].